When the CDC paused diagnostic testing for rabies, mpox, and dozens of other infectious diseases in late March 2026, media coverage focused on two headline-grabbing infections: rabies and mpox. But experts who study infectious disease diagnostic capacity are increasingly drawing attention to a less-covered casualty of the staffing cuts: the CDC's malaria branch, which experienced cuts even deeper than the rabies and poxvirus laboratories.
According to HealthDay reporting on the broader CDC diagnostic cuts, the rabies and poxvirus labs each lost about half their staff — and the malaria branch saw even deeper cuts. CNN confirmed the same finding via the National Public Health Coalition, an organization of former and current CDC workers formed in the wake of the downsizing. The implications are directly tied to patient treatment outcomes, not just surveillance and epidemiology: because different species of malaria-causing Plasmodium parasites require different antimalarial drug regimens, failing to correctly identify the species can result in treatment failure or, in the case of Plasmodium falciparum — the most dangerous species — delayed effective treatment can be fatal.
